



Medicines Made Better.

News Release

Contact: Steven P. Damon
Tel. 404.835.6429
sdamon@alteatherapeutics.com

387 Technology Circle, NW, Suite 100
Atlanta, GA 30313
www.alteatherapeutics.com

Altea Therapeutics Announces Senior R&D Management Appointments to Align Product Development with Needs of Commercialization Partners

Harold Shlevin, former CEO of Solvay Pharmaceuticals, appointed VP, Product Commercial Development; Frank Tagliaferri becomes VP, Research & Development; Michael Hatch becomes VP, Technology Development; Alan Smith becomes VP, Product Development and Project Management

Atlanta, Ga., May 5, 2009. Altea Therapeutics, a leader in advanced transdermal drug delivery systems, announced today senior R&D appointments to strengthen its product development and commercialization capabilities and to align technical operations with the needs of its alliance partners, including Amylin Pharmaceuticals Inc, Eli Lilly and Company, and Hospira, Inc.

Harold Shlevin, PhD, joins the Company as Vice President, Operations and Commercial Development, responsible for commercial product scale-up and manufacturing. Dr. Shlevin brings to Altea Therapeutics a broad range of technical and managerial experience from research and development to commercial operations, including leadership of mid-size and large pharmaceutical and medical device companies. Dr. Shlevin was at Solvay Pharmaceuticals from 1998 where he became President, CEO and a member of its Board of Directors in 2000. Dr. Shlevin previously spent 15 years in senior management roles at Ciba-Geigy Pharmaceuticals and Ciba Vision and most recently he was CEO of Tikvah Therapeutics, a CNS company.

"We are delighted to attract Harold Shlevin to our Company," said Eric Tomlinson, PhD, DSc, President and CEO of Altea Therapeutics. "Harold is an accomplished senior pharmaceutical executive and his experience will enable us confidently to enter the new dimension of product scale up and commercial manufacture in conjunction with our partners."

Altea Therapeutics also announced the following management changes to its R&D organization:

- Frank Tagliaferri, PhD, who has been with the Company since 2004, most recently as its Vice President, Pharmaceutical Sciences, becomes Vice President Research & Development, responsible for the Company's product design and development activities.
- Michael Hatch, formerly Vice President, Engineering, who has been with the Company since 1999, becomes Vice President, Technology Development, focused on optimizing the Company's technology for specific products and on developing new generations of its technology.
- Alan Smith, PhD, who has been with the Company since 2000, most recently as Vice President, Clinical R&D and Regulatory Affairs, becomes Vice President, Product Development and Project Management to align the Company's product development activities and project plans and those of its partners.

About Altea Therapeutics

Altea Therapeutics is a privately held clinical-stage pharmaceutical company with a proprietary platform technology broadly applicable to the transdermal delivery of biological drugs (proteins and carbohydrates) that otherwise would be administered by needle injection or infusion.

The Company's PassPort® Transdermal Delivery System also is uniquely suited for delivering highly water-soluble low molecular weight drugs that otherwise could not be delivered transdermally. These include ionic salt forms of drugs that can be delivered more safely and effectively than by the existing transdermal product, and other low molecular weight drugs with potencies too low to be delivered using conventional transdermal patches.

In April 2009, Altea Therapeutics announced it had entered into a partnership with Amylin Pharmaceuticals, Inc. and Eli Lilly and Company to develop and commercialize a novel daily transdermal patch delivering sustained levels of exenatide. In July 2008, Altea Therapeutics announced it had entered into a partnership with Hospira, Inc. to develop and commercialize an undisclosed transdermal product utilizing the PassPort® Transdermal Delivery System. Altea Therapeutics also is collaborating with several pharmaceutical companies to assess the feasibility of transdermal delivery of certain drugs using its PassPort® Transdermal Delivery System.

In addition to transdermal products that it has announced are in development with its partners, Altea Therapeutics is conducting clinical trials in the United States for other products, including for a Transdermal Basal Insulin Patch designed to provide continuous delivery of insulin for people with type 1 and type 2 diabetes and for a Transdermal Fentanyl Citrate Patch that enables rapid and safe management of moderate to severe pain. The Company is in pre-clinical development with a number of product candidates, including a Parathyroid Hormone Transdermal Patch for the prevention and management of osteoporosis.

Altea Therapeutics is the recipient of the Frost & Sullivan 2007 Technology Innovation Award for its development of the PassPort Transdermal Delivery System and was named one of the top 50 technology companies in the Southeast of the U.S. in 2008 by TechJournal South.

Additional information about Altea Therapeutics may be found at www.alteatherapeutics.com.

NOTE: Altea Therapeutics, PassPort, Medicines Made Better. are either registered trademarks or trademarks of Altea Therapeutics Corporation, in the USA and/or other countries. All other brand names, product names, or trademarks belong to their respective holders.

The statements in this press release regarding the products of Altea Therapeutics in development, product development plans, and projected financial results, are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the ability of Altea Therapeutics to both complete the design, development, and manufacturing process development of its products, manufacture and commercialize its products, obtain product and manufacturing approvals from regulatory agencies, manage its growth and expenses, finance its activities and operations, as well as marketplace acceptance of its products.